Best Pharmaceutical Stocks To Follow Today - September 25th

Key Points

• Investors should focus on five pharmaceutical stocks today: Eli Lilly, Pfizer, Novo Nordisk, SciSparc, and McKesson, which are highlighted for their significant trading volume and potential growth.
• Eli Lilly has made a notable breakthrough with its oral GLP-1 treatment, which could significantly impact the diabetes treatment landscape.
• SciSparc is focusing on cannabinoid therapies, developing various treatments including options for Tourette syndrome and chronic pain.

Eli Lilly and Company, Pfizer, Novo Nordisk A/S, SciSparc, and McKesson are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies whose primary business is the research, development and manufacturing of prescription drugs and medical therapies. Investors in these stocks seek to profit from the companies’ drug pipelines, patent protections and regulatory approvals, while accepting risks tied to clinical trial outcomes, patent expirations and shifting healthcare policies. Because drug discovery can be capital-intensive and uncertain, pharmaceutical stocks often exhibit higher volatility and event-driven price swings than more diversified sectors. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read Our Latest Research Report on LLY

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read Our Latest Research Report on PFE

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Read Our Latest Research Report on NVO

SciSparc (SPRC)

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.

Read Our Latest Research Report on SPRC

McKesson (MCK)

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

Read Our Latest Research Report on MCK